Acurx Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Acurx is a clinical-stage biopharmaceutical company developing antibiotics, led by ibezapolstat for Clostridioides difficile infection (CDI). It has no approved products and has generated no revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.56 million | $1.02 million; up 53% |
| General and administrative expense | $2.82 million | $1.89 million; up 50% |
| Total operating expenses and net loss | $4.38 million | $2.90 million; loss increased 51% |
| Basic and diluted loss per share | $0.28 | $0.25 |
| Cash from operating activities | $(3.06) million | $(1.93) million |
| Cash from financing activities | $4.51 million | None |
| Cash and cash equivalents | $8.92 million at March 31 | $7.47 million at December 31, 2023 |
| Total liabilities | $3.11 million | $3.04 million at December 31, 2023 |
| Working capital | $6.0 million | Not provided for the comparable quarter |
There is no reported debt. Gross margin is not applicable because the company has no revenue. Accumulated deficit was $57.6 million at quarter-end. Cash increased by $1.45 million during the quarter, principally because $4.30 million of net ATM proceeds and $0.21 million from warrant exercises exceeded operating cash use.
Material changes and financing
- Net loss rose by $1.47 million year over year. Management attributed higher R&D expense mainly to manufacturing costs and higher G&A expense mainly to professional fees and share-based compensation.
- The company sold 1,121,793 shares through its at-the-market (ATM) program during Q1, generating $4.4 million gross and $4.3 million net. At March 31, approximately $9.9 million remained available under the $17.0 million program.
- Common shares outstanding increased from 14,468,229 at December 31, 2023 to 15,757,102 at March 31, 2024. The filing reports 15,843,102 shares issued and outstanding as of May 14, 2024.
- At March 31, 6,136,245 warrants and 3,820,000 options were outstanding; these potential shares were excluded from diluted loss per share as antidilutive.
Outlook, risks and unusual items
- Going concern and funding: Management states that available cash is not sufficient for anticipated cash requirements for at least 12 months from the financial statement issuance date. The company expects continuing losses and negative cash flows, has no committed additional funding, and plans to pursue equity financing and grants. It cautions that funding may not be available on acceptable terms or at all; these conditions raise substantial doubt about its ability to continue as a going concern. The financial statements include no adjustments for this uncertainty.
- Clinical development: The company plans to advance ibezapolstat to Phase 3 and held an FDA End-of-Phase 2 meeting in April 2024; it expected final meeting minutes in May. No specific Phase 3 start date or quantified guidance is provided.
- Phase 2 evidence: In the small per-protocol populations reported, clinical cure was 15/16 (94%) for ibezapolstat and 14/14 (100%) for vancomycin in Phase 2b; the combined ibezapolstat Phase 2a/2b cure rate was 25/26 (96%). Phase 2b was discontinued early after consultation with advisers, citing slow enrollment and site costs, not safety concerns. The company cautions that early-stage results may not predict Phase 3 outcomes.
- Key risks: Regulatory approval and Phase 3 success are uncertain; the company depends heavily on ibezapolstat, third-party manufacturers and clinical vendors, and future external financing. Additional equity financing may dilute shareholders. One bank held most cash, and approximately $8.9 million was not fully FDIC-insured. Two vendors represented significant shares of R&D spending, and one represented about 54% of accounts payable and accrued expenses at quarter-end.
- Commitments and legal matters: A $150,000 development milestone payable is included in accrued expenses; the asset purchase agreement also provides for milestone payments and royalties equal to 4% of future net sales. Management reports no litigation likely to have a material adverse effect. Disclosure controls were assessed as effective; no material changes in internal control over financial reporting were reported.
Important facts for investors to verify
- Whether the FDA meeting minutes confirm a viable Phase 3 design, requirements, timing and costs.
- Current cash runway and funding needs, including subsequent ATM sales, grants, partnerships or other financing, and the resulting dilution.
- Final analyses and safety data from the small Phase 2 trial, and whether Phase 3 results support the preliminary efficacy signals.
- Manufacturing readiness, supply continuity and vendor concentration as development advances.
- Outstanding warrants, options and share count updates after May 14, 2024.